Cart 0 $0.00
IRE favicon


Resource ID: #20287
Subject: Pharmaceuticals
Source: Wall Street Journal (New York)
Date: 2001-05-21


The Wall Street Journal looks at Bristol-Myers' fight to woo patients to a new diabetes medication that isn't substantially different, but is shielded from generic competition. "If the aggressive marketing campaign succeeds, it could mean that tens of thousands of elderly and poor patients--groups for which diabetes has reached epidemic proportions--will keep using the high-priced alternatives from Bristol-Myers."

This file is not available for digital download. IRE members may place an order by emailing

109 Lee Hills Hall, Missouri School of Journalism   |   221 S. Eighth St., Columbia, MO 65201   |   573-882-2042   |   |   Privacy Policy
apartmentpenciluserscalendar-fullcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram
My cart
Your cart is empty.

Looks like you haven't made a choice yet.